Business
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 202
About this update from Neumora Therapeutics, Inc.
[{"type":"image","alt":"Neumora Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neumora Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_ktBLath.hAycAMjdGu3YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTc5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0","width":183,"height":40}},"lazy":false},{"type":"text","content":"On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025","length":101,"tagName":"p"},{"type":"text","content":"Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026","length":203,"tagName":"p"},{"type":"text","content":"Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025","length":93,"tagName":"p"},{"type":"text","content":"Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027","length":133,"tagName":"p"},{"type":"text","content":"Company to host conference call today at 4:30 p.m. ET","length":53,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":357,"tagName":"p"},{"type":"text","content":"“Our vision in building Neumora is to make a difference for people living with brain diseases. With our diverse, industry-leading pipeline, multiple upcoming clinical catalysts, experienced team and strong financial foundation, we are making important progress towards achieving that goal,” said Paul L. Berns, chairman and chief executive officer, Neumora. “We are advancing enrollment for the Phase 1b signal-seeking study of NMRA-511 in Alzheimer’s disease agitation, have taken important steps to help optimize the navacaprant program in major depress...